152 related articles for article (PubMed ID: 25885468)
21. Secondary malignant neoplasms after osteosarcoma: early onset and cumulative alkylating agent dose dependency.
Kim SH; Shin KH; Seok SO; Cho YJ; Noh JK; Suh JS; Yang WI
Ann Surg Oncol; 2015 Mar; 22(3):859-65. PubMed ID: 25192682
[TBL] [Abstract][Full Text] [Related]
22. The outcomes and prognostic factors in patients with osteosarcoma according to age: a Japanese nationwide study with focusing on the age differences.
Tsuda Y; Ogura K; Shinoda Y; Kobayashi H; Tanaka S; Kawai A
BMC Cancer; 2018 May; 18(1):614. PubMed ID: 29855362
[TBL] [Abstract][Full Text] [Related]
23. [The effect of resistance-related proteins on the prognosis and survival of patients with osteosarcoma: an immunohistochemical analysis].
Ozger H; Eralp L; Atalar AC; Toker B; Esberk Ateş L; Sungur M; Bilgiç B; Ayan I
Acta Orthop Traumatol Turc; 2009; 43(1):28-34. PubMed ID: 19293613
[TBL] [Abstract][Full Text] [Related]
24. Pelvis and extremity osteosarcoma with similar tumor volume have an equivalent survival.
Song WS; Cho WH; Jeon DG; Kong CB; Kim MS; Lee JA; Eid AS; Kim JD; Lee SY
J Surg Oncol; 2010 Jun; 101(7):611-7. PubMed ID: 20461769
[TBL] [Abstract][Full Text] [Related]
25. Elevated expression of AKT2 correlates with disease severity and poor prognosis in human osteosarcoma.
Zhu Y; Zhou J; Ji Y; Yu B
Mol Med Rep; 2014 Aug; 10(2):737-42. PubMed ID: 24919955
[TBL] [Abstract][Full Text] [Related]
26. Postrelapse Prognostic Factors in Nonmetastatic Osteosarcoma: A Single-institution Experience.
Berlanga P; Cañete A; Salom M; Montalar J; Guasp M; Marco A; Castel V
J Pediatr Hematol Oncol; 2016 Apr; 38(3):176-81. PubMed ID: 26925713
[TBL] [Abstract][Full Text] [Related]
27. Vitronectin significantly influences prognosis in osteosarcoma.
Shi K; Lan RL; Tao X; Wu CY; Hong HF; Lin JH
Int J Clin Exp Pathol; 2015; 8(9):11364-71. PubMed ID: 26617861
[TBL] [Abstract][Full Text] [Related]
28. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
29. [Multivariate analysis for prognostic factors among 43 patients with osteosarcoma].
Zhang B; Pang QJ; Zhang HJ; Yuan Y
Zhongguo Gu Shang; 2011 Dec; 24(12):982-6. PubMed ID: 22276503
[TBL] [Abstract][Full Text] [Related]
30. [Value of thallium-201 scintigraphy in assessment of neoadjuvant chemotherapy for osteosarcoma].
Huang ZK; Lou C; Fang XQ
Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):769-72. PubMed ID: 20021831
[TBL] [Abstract][Full Text] [Related]
31. [Clinico-radiological assessment of chemotherapy for osteosarcoma received prior to surgery].
Krzhivitskiĭ PI; Vesnin AG; Kolygin BA; Turkevich EA; Zasul'skiĭ FIu
Vopr Onkol; 2004; 50(4):430-4. PubMed ID: 15605766
[TBL] [Abstract][Full Text] [Related]
32. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
[TBL] [Abstract][Full Text] [Related]
33. High-grade surface osteosarcoma: a review of 25 cases from the Rizzoli Institute.
Staals EL; Bacchini P; Bertoni F
Cancer; 2008 Apr; 112(7):1592-9. PubMed ID: 18300258
[TBL] [Abstract][Full Text] [Related]
34. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma.
Bernthal NM; Federman N; Eilber FR; Nelson SD; Eckardt JJ; Eilber FC; Tap WD
Cancer; 2012 Dec; 118(23):5888-93. PubMed ID: 22648705
[TBL] [Abstract][Full Text] [Related]
35. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma.
Uchibori M; Nishida Y; Nagasaka T; Yamada Y; Nakanishi K; Ishiguro N
Int J Oncol; 2006 Jan; 28(1):33-42. PubMed ID: 16327977
[TBL] [Abstract][Full Text] [Related]
36. Modeling Continuous Prognostic Factors in Survival Analysis: Implications for Tumor Staging and Assessing Chemotherapy Effect in Osteosarcoma.
Cates JMM
Am J Surg Pathol; 2018 Apr; 42(4):485-491. PubMed ID: 29200101
[TBL] [Abstract][Full Text] [Related]
37. Prognosis for patients who have osteosarcoma with skip metastasis.
Wuisman P; Enneking WF
J Bone Joint Surg Am; 1990 Jan; 72(1):60-8. PubMed ID: 2295674
[TBL] [Abstract][Full Text] [Related]
38. Tumor volume change after chemotheraphy as a predictive factor of disease free survival for osteosarcoma.
Moon SH; Shin KH; Suh JS; Yang WI; Noh JK; Hahn SB
Yonsei Med J; 2005 Feb; 46(1):119-24. PubMed ID: 15744814
[TBL] [Abstract][Full Text] [Related]
39. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
Hawkins DS; Arndt CA
Cancer; 2003 Dec; 98(11):2447-56. PubMed ID: 14635080
[TBL] [Abstract][Full Text] [Related]
40. Metachronous skeletal osteosarcoma in patients treated with adjuvant and neoadjuvant chemotherapy for nonmetastatic osteosarcoma.
Aung L; Gorlick R; Healey JH; Shi W; Thaler HT; Shorter NA; Huvos AG; Meyers PA
J Clin Oncol; 2003 Jan; 21(2):342-8. PubMed ID: 12525528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
